Consensus Sagimet Biosciences Inc.

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
4.62 ^USD	+5.48%		+4.05%	-14.76%

May. 15	Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 06	Sagimet Biosciences Names Thierry Chauche CFO	MT

9ab.Ai4bUoX5Ima5yY6twqZDgX8WFaTg3WA2DBBFZ81nDLg.bmQuFeKPdgrmmf7Btfd3y0lzQ--MiVRzdntzKaAxU9kwG1kW75R3L4q4vg~4e3c46525648eac14e6c0279144231b8

HC Wainwright Starts Sagimet Biosciences With Buy Rating, $32 Price Target	May. 02	MT
Goldman Sachs Adjusts Sagimet Biosciences' Price Target to $27 From $37, Maintains Buy Rating	Mar. 26	MT
Leerink Partners Initiates Sagimet Biosciences With Outperform Rating, $26 Price Target	Mar. 25	MT
JMP Securities Adjusts Price Target on Sagimet Biosciences to $46 From $47, Maintains Market Outperform Rating	Feb. 07	MT
Goldman Sachs Raises Price Target on Sagimet Biosciences to $37 From $30, Keeps Buy Rating	Jan. 23	MT
JMP Securities Raises Price Target on Sagimet Biosciences to $47 From $31, Maintains Market Outperform Rating	Jan. 23	MT
TD Cowen Initiates Sagimet Biosciences With Outperform Rating	23-08-08	MT
Goldman Sachs Initiates Sagimet Biosciences at Buy With $33 Price Target	23-08-08	MT
Piper Sandler Initiates Sagimet Biosciences With Overweight Rating, $67 Price Target	23-08-08	MT
JMP Securities Starts Sagimet Biosciences With Market Outperform Rating, $30 Price Target	23-08-08	MT

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.62 USD

Average target price

40 USD

Spread / Average Target

+765.80%

High Price Target

67 USD

Spread / Highest target

+1,350.22%

Low Price Target

26 USD

Spread / Lowest Target

+462.77%